Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY ® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New

Teva Pharmaceuticals announced real-world data at the 2025 Psych Congress Elevate Annual Meeting, highlighting the benefits of UZEDY (risperidone) versus second-generation oral antipsychotics for schizophrenia treatment; studies showed lower relapse rates, improved adherence, and reduced healthcare resource utilization with UZEDY. Additionally, Phase 3 SOLARIS data for TEV-’749, a long-acting injectable olanzapine, demonstrated no post-injection delirium/sedation syndrome (PDSS) events, suggesting a potentially safer alternative in the schizophrenia treatment landscape, though TEV-'749 is still investigational.

Analysis

Teva Pharmaceutical Industries Ltd. presented compelling real-world and clinical data for its schizophrenia treatments at the 2025 Psych Congress Elevate Annual Meeting, reinforcing its position in the neuroscience market. Real-world claims studies for UZEDY® (risperidone), an already approved extended-release injectable, demonstrated superior outcomes compared to second-generation daily oral antipsychotics (SGOAs). Specifically, UZEDY was associated with a lower relapse rate (9.0% vs. 15.4% for SGOAs), longer mean time to relapse (94 days vs. 61 days), and significantly better medication adherence (71.3% vs. 52.8%). Furthermore, UZEDY showed a marked reduction in healthcare resource utilization, including shorter hospital stays (8 days vs. 16 days) and lower mean all-cause HCRU costs ($18,796 vs. $26,376 for SGOAs). Concurrently, Teva reported positive Phase 3 SOLARIS data for its investigational once-monthly subcutaneous long-acting injectable (LAI) olanzapine, TEV-’749. Crucially, no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events were observed after over 3,400 injections, a significant potential advantage given PDSS concerns with other olanzapine LAIs. TEV-’749 also met its primary efficacy endpoint, showing statistically significant improvements in PANSS total scores versus placebo, with a safety profile consistent with approved olanzapine. Both UZEDY and the investigational TEV-’749 utilize Teva's proprietary SteadyTeq™ copolymer technology, indicating a strategic focus on differentiated LAI delivery systems. These findings highlight UZEDY's current value proposition and TEV-’749's potential to address a critical unmet need in schizophrenia treatment, potentially expanding Teva's market share in this therapeutic area.

Key Decisions for Investors

• The strong real-world data for UZEDY may bolster its commercial uptake and revenue contribution, warranting monitoring of its sales trajectory and market share gains within the schizophrenia LAI segment.
• Positive Phase 3 results for TEV-’749, particularly the absence of PDSS events, significantly de-risk its development and suggest a strong competitive profile if approved; investors should watch for regulatory submission and review timelines.
• Given Teva's focus on LAIs leveraging its SteadyTeq™ technology, these developments support the company's innovation strategy in neuroscience, potentially leading to sustained growth in this franchise; however, the investigational status of TEV-'749 means future success is not guaranteed and carries inherent clinical and regulatory risks.